🔗 Share this article

Given that America proceeds with historic revisions to its vaccine guidelines, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by questioning Covid shots during the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to announce sweeping revisions to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US at odds with many the global community with little proof for benefit. The announcement has been pushed back until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

A New Direction at the Agency

The acting appointment may indicate a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US to become more in line with the Danish model, a country with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccines – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Qualifications

Høeg has no obvious track record in medication creation, regulation or management, which has been standard for former directors of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She lacks background in drug approvals.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who led the center have had.”

CDER has an immense workload at the FDA, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and more, and each of these have to be managed,” Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant management aspect to the job, which oversees more than 5,000 staff members. “It is a massive management job, if you execute it properly,” she concluded.

Agency Reaction and Contentious Policies

When asked about questions about Dr. Høeg's credentials and whether this selection signifies greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “inquiries stem from flawed assumptions”.

“Her resume matches the duties of her position,” the official explained, citing the time Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a disputed expedited medication authorization process that reportedly troubled her predecessors. “By what process are these therapies being picked for this voucher program? Who makes the choices?” Howard asked. “There is a lot of secrecy happening at the agency right now.”

Overall, he remarked, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, aside from shots.”

Established History on Vaccines

Regarding immunizations, Høeg has a more documented, if concerning, track record, some experts observe. She released a study using unverified volunteer-provided data to estimate the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the new federal leadership included revising rules for recently developed shots and halting “non-essential” immunizations, she remarked post-election on a audio program. At the FDA, Dr. Høeg has according to sources proposed barring young men from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who begins with her preconceived notions and works backwards to accommodate the evidence in a very misleading, untruthful way,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow contrarians, {like|